ArticleCancer medicine2020
SARS-CoV-2 infections in cancer outpatients-Most infected patients are asymptomatic carriers without impact on chemotherapy.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Guideline
- Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis.Proceedings of the National Academy of Sciences of the United States of America · 2021Pooled it
- The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review.Annals of internal medicine · 2021Pooled it
- A practical approach to febrile cancer patients: Diagnostic stewardship in Oncology units.F1000Research · 2024Article
- SARS-CoV-2 infection as a potential risk factor for the development of cancer.Frontiers in molecular biosciences · 2023Review
- Influence of the COVID-19 pandemic in the gastrointestinal oncology setting: An overview.World journal of gastrointestinal pathophysiology · 2022Review
- Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.Cancer discovery · 2022Review
- Routine COVID-19 testing may not be necessary for most cancer patients.Scientific reports · 2021Article
- Article
- Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.BMC cancer · 2021Observational
- Management and Thinking on the Treatment of Cancer Patients During the COVID-19.Frontiers in molecular biosciences · 2021Review
- Chemotherapy During Active SARS-CoV2 Infection: A Case Report and Review of the Literature.Frontiers in oncology · 2021Review
- SARS-CoV-2 infections in cancer outpatients-Most infected patients are asymptomatic carriers without impact on chemotherapy.Cancer medicine · 2020Article
- The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy.Frontiers in public healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncologic patients are regarded as the population most at risk of developing a severe course of COVID-19 due to the fact that malignant diseases and chemotherapy often weaken the immune system. In the face of the ongoing SARS-CoV-2 pandemic, how particular patients deal with this infection remains an important question. In the period between the 15 and 26 April 2020, a total of 1227 patients were tested in one of seven oncologic outpatient clinics for SARS-CoV-2, regardless of symptoms, employing RT-qPCR. Of 1227 patients, 78 (6.4%) were tested positive of SARS-CoV-2. Only one of the patients who tested positive developed a severe form of COVID-19 with pneumonia (CURB-65 score of 2), and two patients showed mild symptoms. Fourteen of 75 asymptomatic but positively tested patients received chemotherapy or chemo-immunotherapy according to their regular therapy algorithm (±4 weeks of SARS-CoV-2 test), and 48 of 78 (61.5%) positive-tested patients received glucocorticoids as co-medication. None of the asymptomatic infected patients showed unexpected complications due to the SARS-CoV-2 infection during the cancer treatment. These data clearly contrast the view that patients with an oncologic disease are particularly vulnerable to SARS-CoV-2 and suggest that compromising therapies could be continued or started despite the ongoing pandemic. Moreover the relatively low appearance of symptoms due to COVID-19 among patients on chemotherapy and other immunosuppressive co-medication like glucocorticoids indicate that suppressing the response capacity of the immune system reduces disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.